NNBP - Nanobac Pharmaceuticals Inc. (Bulls Board) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NNBP - Nanobac Pharmaceuticals Inc. (Bulls Board)

NNBP 0.0001000

0.0%

Mar 7 3:00 PM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: donpat	5/25/2007 9:29:09 AM
	of 106

TACT - Trial to Assess Chelation Therapy Study start: September 2003; Expected completion: July 2009 Total Enrollment: 1950 Study start: September 2003; Expected completion: July 2009 EDTA chelation therapy involves repeated administrations of a synthetic amino acid to reduce atherosclerotic plaque and other mineral deposits throughout the cardiovascular system. Participants will be randomly assigned to receive 40 infusions of either the standard chelation solution or placebo. The primary endpoint of this trial will be a composite of all cause mortality, myocardial infarction, stroke, hospitalization for angina and hospitalization for congestive heart failure. The results of TACT will provide either a significant positive result or an informative null result upon which rational clinical decision-making and health policy can be based. Eligibility Ages Eligible for Study: 50 Years and above, Genders Eligible for Study: Both CriteriaInclusion Criteria for Participants: Heart attack at least 6 weeks prior to study start clinicaltrials.gov

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next